Journal
ONCOLOGIST
Volume 15, Issue 6, Pages 577-583Publisher
WILEY
DOI: 10.1634/theoncologist.2010-0029
Keywords
Bevacizumab; sVEGFR-1; Biomarker; Rectal cancer; Chemoradiation; Toxicity
Categories
Funding
- NIH [R21-CA99237, P01-CA80124, R01-CA115767, R01-CA85140, R01-CA126642]
- Federal Share/NCI Proton Beam Program Income
- National Foundation for Cancer Research
- NATIONAL CANCER INSTITUTE [R01CA115767, P01CA080124, R01CA085140, R21CA099237, T32CA073479, R01CA126642] Funding Source: NIH RePORTER
Ask authors/readers for more resources
We explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002-2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with vascular normalization-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting. The Oncologist 2010;15:577-583
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available